Contact
searchSearch
HMP Global

Hemophilia Topic Center

Featured Article

News
HAVEN 7 Trial Evaluates Emicizumab Prophylaxis in Infants With Hemophilia A
06/19/2024
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy,...
06/19/2024
First Report Managed Care
News
Factor VIII Market Expected to Grow Over Next 5 Years
05/24/2024
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human...
05/24/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
The Impact of Inhibitors on Surgical Management in Patients With Hemophilia
04/04/2024
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in...
04/04/2024
First Report Managed Care
News
Patient Education on AAV Vectors for Hemophilia Essential to Prevent ‘Buyer’s Remorse’
11/10/2023
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
Changing Trends in Hemophilia Treatment
10/27/2023
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies...
10/27/2023
First Report Managed Care
News
Acquired Hemophilia A Treatment Gaps Identified
10/16/2023
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study...
10/16/2023
First Report Managed Care
News
Gene Therapy for Hemophilia: Considering Therapeutic Value, Patient Selection
08/09/2023
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review...
08/09/2023
First Report Managed Care
News
High Industry Payments to Hemophilia Center Directors May Be Cause for Concern
07/21/2023
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess...
07/21/2023
First Report Managed Care
News
Disparities Between Guideline Recommendations, Implementation of Pharmacokinetic Dosing for Bleeding Disorders
07/17/2023
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping...
07/17/2023
First Report Managed Care
News
First Gene Therapy for Severe Hemophilia A Is Approved
06/29/2023
This approval comes after a safety and effectiveness trial showed that the treatment improved participants’ annualized bleeding rate after 3 years.
This approval comes after a safety and effectiveness trial showed that the treatment improved participants’ annualized bleeding rate after 3 years.
This approval comes after a...
06/29/2023
Population Health
From Population Health

Newsfeed

News
HAVEN 7 Trial Evaluates Emicizumab Prophylaxis in Infants With Hemophilia A
06/19/2024
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy,...
06/19/2024
First Report Managed Care
News
Factor VIII Market Expected to Grow Over Next 5 Years
05/24/2024
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human...
05/24/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
The Impact of Inhibitors on Surgical Management in Patients With Hemophilia
04/04/2024
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in...
04/04/2024
First Report Managed Care
News
Patient Education on AAV Vectors for Hemophilia Essential to Prevent ‘Buyer’s Remorse’
11/10/2023
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
Changing Trends in Hemophilia Treatment
10/27/2023
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies...
10/27/2023
First Report Managed Care
News
Acquired Hemophilia A Treatment Gaps Identified
10/16/2023
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study...
10/16/2023
First Report Managed Care
News
Gene Therapy for Hemophilia: Considering Therapeutic Value, Patient Selection
08/09/2023
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review...
08/09/2023
First Report Managed Care
News
High Industry Payments to Hemophilia Center Directors May Be Cause for Concern
07/21/2023
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess...
07/21/2023
First Report Managed Care
News
Disparities Between Guideline Recommendations, Implementation of Pharmacokinetic Dosing for Bleeding Disorders
07/17/2023
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping...
07/17/2023
First Report Managed Care
Conference Coverage
Impact of Prior Authorization Removal on SGLT2 Inhibitor Utilization
12/10/2024
At the 2024 ASHP Midyear Clinical Meeting, researchers presented on the impact of removing prior authorization (PA) restrictions on the utilization of sodium-glucose co-transporter-2 inhibitors (SGLT2i) in a primary care safety net clinic...
At the 2024 ASHP Midyear Clinical Meeting, researchers presented on the impact of removing prior authorization (PA) restrictions on the utilization of sodium-glucose co-transporter-2 inhibitors (SGLT2i) in a primary care safety net clinic...
At the 2024 ASHP Midyear...
12/10/2024
Pharmacy Learning Network
Conference Coverage
The Changing Role of Pharmacists in Telepharmacy for Chronic Disease Management
12/09/2024
Research at the 2024 ASHP Midyear Clinical Meeting explores pharmacists' evolving role in telepharmacy for chronic disease management, uncovering challenges and strategies to improve patient communication, optimize technology support, and...
Research at the 2024 ASHP Midyear Clinical Meeting explores pharmacists' evolving role in telepharmacy for chronic disease management, uncovering challenges and strategies to improve patient communication, optimize technology support, and...
Research at the 2024 ASHP...
12/09/2024
Pharmacy Learning Network
News
Machine Learning Advances Revolutionize Pulmonary Arterial Hypertension Diagnosis
12/09/2024
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
Machine learning techniques such...
12/09/2024
First Report Managed Care
News
Immune-Related Adverse Events With ICIs Linked to Improved Survival in Metastatic NSCLC
12/09/2024
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically...
12/09/2024
First Report Managed Care
News
Antiseizure Drugs for Tumor-Related Epilepsy Require Careful Management
12/04/2024
A recent consensus review discusses current management strategies for brain tumor-related epilepsy, with an emphasis on the role of antiseizure medications and surgical resection.
A recent consensus review discusses current management strategies for brain tumor-related epilepsy, with an emphasis on the role of antiseizure medications and surgical resection.
A recent consensus review...
12/04/2024
First Report Managed Care
News
Algorithm Predicts Seizure Control Outcomes After Brain Resection Surgery
12/03/2024
A machine learning algorithm predicted seizure control after temporal lobe resection using just 5 minutes of peri-ictal data from a scalp electroencephalogram (EEG) that is already part of the standard universal presurgical evaluation.
A machine learning algorithm predicted seizure control after temporal lobe resection using just 5 minutes of peri-ictal data from a scalp electroencephalogram (EEG) that is already part of the standard universal presurgical evaluation.
A machine learning algorithm...
12/03/2024
First Report Managed Care
News
Cognitive Dysfunction More Likely in Older Adults With Asthma
12/03/2024
Asthma was associated with cognitive dysfunction in a sample of adults aged 60 years and older from the National Health and Nutrition Examination Survey (NHANES).
Asthma was associated with cognitive dysfunction in a sample of adults aged 60 years and older from the National Health and Nutrition Examination Survey (NHANES).
Asthma was associated with...
12/03/2024
First Report Managed Care
News
Emicizumab as a Potential Treatment Pathway for Select Hemophilia B Cases
11/22/2024
New research highlights the potential of emicizumab, traditionally used to treat hemophilia A (HA), as a promising alternative therapy for certain hemophilia B (HB) genotypes.
New research highlights the potential of emicizumab, traditionally used to treat hemophilia A (HA), as a promising alternative therapy for certain hemophilia B (HB) genotypes.
New research highlights the...
11/22/2024
First Report Managed Care
News
Sex Differences in Survival Among Patients With Pulmonary Arterial Hypertension
11/22/2024
A recent study investigated the “sex paradox” in pulmonary arterial hypertension, which highlights better survival outcomes in women despite more severe disease presentation.
A recent study investigated the “sex paradox” in pulmonary arterial hypertension, which highlights better survival outcomes in women despite more severe disease presentation.
A recent study investigated the...
11/22/2024
First Report Managed Care
News
Patisiran Shows Promise in Treating Hereditary Transthyretin Amyloidosis With Polyneuropathy
11/22/2024
Patisiran offers promising benefits for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare and fatal genetic disorder characterized by amyloid fibril deposits affecting multiple organs.
Patisiran offers promising benefits for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare and fatal genetic disorder characterized by amyloid fibril deposits affecting multiple organs.
Patisiran offers promising...
11/22/2024
First Report Managed Care
FRMC Volume 21, Issue 4

Current Issue

October/November/December Volume 21, Issue 4, First Report Managed Care
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use